Tripped up by the FDA, Novartis says it is dropping out of the US race to win an OK for a blockbuster Rituxan rival
Novartis may have had little trouble getting an EU approval for their knockoff of Roche’s Rituxan last year, but they’ve reached a dead end in the US.
The pharma giant announced Friday that it is throwing in the towel on its campaign to win an OK at the FDA after regulators demanded additional information — throwing a monkey wrench into its timeline as a host of rivals pressed for a green light.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.